Is bimetinib/bemetinib available in China? Is it sold domestically?

Binimetinib/Binimetinib is an oral drug that targets MEK1/2 and has potential anti-tumor activity. It is mainly used to treat specific types of cancer, especially melanoma and non-small cell lung cancer. Since its development, the drug has received widespread attention around the world because it has shown good efficacy and safety in clinical trials.

As of20241February, bimetinib has not yet been officially launched in China. However, with the accelerated approval process of anti-cancer drugs by the National Medical Products Administration and the increasing demand for innovative treatment methods in the Chinese market, it is expected that there may be more opportunities and policy support in the future to enable anti-cancer drugs, including bimetinib, to enter the Chinese market.

As a selective MEK inhibitor, bimetinib binds to and inhibits the activities of MEK1 and MEK2 without competing with ATP, thereby effectively interfering with the MEK signaling pathway. MEK1/2 is an important component in the mitogen-activated protein kinase pathway and is involved in regulating various biological processes such as cell proliferation and survival. In many types of tumors, MEK1/2 activity is often upregulated, promoting the growth and spread of tumor cells. The mechanism of action of bimetinib makes it show good prospects in the treatment of tumors related to the RAS/RAF/MEK/ERK pathway.

In the international market, bimetinib has been approved by some countries and regions and is mainly used to treat specific types of melanoma. Patients can achieve better results when receiving combination therapies, especially when combined with other immunotherapies or targeted therapies. However, despite the gradual increase in clinical applications abroad, there is no clear news on the progress of bimetinib's launch in China.

Reference materials:https://www.amoydiagnostics.com/about/press-releases/91